TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ERAS

Erasca Inc

Healthcare · Biotechnology

14.80$ -3.7% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Income Statement ERAS
Line item 2019 2020 2021 2022 2023 2024 2025
+74.2% +53.5% +218.6% +41.3% +2.0% -18.3%
+953.2% -27.0% +52.1% -7.7% +11.1% -19.5%
+116.5% +184.2% +45.9% +14.3% +10.7% -7.6%
+721.8% +13.5% +97.3% -43.7% +30.3% -28.6%
+16,525.3% +260.5%
-61.7% -117.0%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?